7621-94-5

Usage

Uses

Used in Pharmaceutical Synthesis:
O-methyltyrosinamide is used as a precursor in the pharmaceutical industry for the synthesis of various drug compounds. Its unique chemical structure makes it a valuable building block in the development of new medications.
Used in Neurodegenerative Disease Research:
In the field of biomedical research, O-methyltyrosinamide is used as a potential therapeutic agent for neurodegenerative diseases. Its specific properties are being studied to understand its effects and potential benefits in treating such conditions.
Used in Cancer Research:
O-methyltyrosinamide is also utilized in cancer research as a potential therapeutic agent. Its unique structure and properties are being investigated for their possible role in the treatment and management of cancer.
Used in Biomedical Research:
In the broader scope of biomedical research, O-methyltyrosinamide serves as a valuable tool for studying the mechanisms of disease and the development of novel therapeutic strategies, given its potential applications in various medical fields.

Upstream product

• 56876-12-1 (S)-2-(1,3-dioxoisoindolin-2-yl)-3-(4-methoxyphenyl)propanamide 
• 7479-01-8 O-methyl-L-tyrosine methyl ester hydrochloride 
• 53267-93-9 O-methyl-N-tert-butoxycarbonyl-L-tyrosine 

Downstream Products

• 145232-12-8 3-tert-butoxycarbonylamino-N-[1-carbamoyl-2-(4-methoxy-phenyl)-ethyl]-succinamic acid benzyl ester 
• 96813-47-7 (S)-3-(4-methoxy-phenyl)-propane-1,2 diamine 
• 774157-11-8 (S)-3-Amino-N-[(S)-1-carbamoyl-2-(4-methoxy-phenyl)-ethyl]-succinamic acid benzyl ester 

Relevant academic research and scientific papers

3, 5-disubstituted hydantoin compound as well as preparation method and application thereof

The invention provides a 3, 5-disubstituted hydantoin compound as well as a preparation method and an application thereof. The structure of the compound is shown in formula I in the description. The application of the 3, 5-disubstituted hydantoin compound shown in the formula I or solvates, hydrates or salts of the compound in preparation of medicines for treating Alzheimer's disease, vascular dementia and other dementia diseases with memory impairment also belongs to the protection scope. Animal experiments prove that the compound has the effect of saving memory of animal models, has high safety, does not have mutagenicity, can stay in blood for several hours after oral administration and intravenous injection, and can enter the brain.

Control of 6-Exo and 7-Endo cyclizations of alkynylamides using platinum and bismuth catalysts

The rules of cyclization: Alkynylamides are regioselectively cycloisomerized into piperazin-2-one and 1,4-diazepan-2-one derivatives by using catalytic amounts of appropriate metal catalysts. A 6-exo-dig addition proceeds in the presence of Bi(OTf)3, while the 7-endo-dig addition occurs with PtCl2 for the same substrate. (see scheme; Ns=o- nitrobenzenesulfonyl, Ts=p-toluenesulfonyl, Cbz=benzyloxycarbonyl, DCE=dichloroethane) Copyright

Photophysical Properties of Tyrosine and Its Simple Derivatives Studied by Time-Resolved Fluorescence Spectroscopy, Global Analysis, and Theoretical Calculations

The photophysical properties of tyrosine and its derivatives with free and blocked functional groups in water were studied by steady-state and time-resolved fluorescence spectroscopy and global analysis. Tyrosine fluorescence intensity decays in water at

Mechanism of fluorescence quenching of tyrosine derivatives by amide group

The difference between fluorescence lifetimes of the following amino acids: phenylalanine (Phe), tyrosine (Tyr), (O-methyl)tyrosine (Tyr(Me)), (3-hydroxy)tyrosine (Dopa), (3,4-dimethoxy)phenylalanine (Dopa(Me)2) and their amides was used to tes